Supplementary Material

Crosslinking of CD20 and CD38 by Drug-Free Macromolecular Therapeutics Enhances B Cell Apoptosis

M. Tommy Gambles^{1,2}, Jiahui Li^{1,2}, D. Christopher Radford^{1,4}, Douglas Sborov³, Paul Shami³, Jiyuan Yang^{1,2*}, Jindřich Kopeček^{1,2,4*}

¹ Center for Controlled Chemical Delivery, University of Utah, Salt Lake City, UT 84112, USA
² Department of Pharmaceutics and Pharmaceutical Chemistry, University of Utah, Salt Lake City, UT 84112, USA
³ Huntsman Cancer Institute, University of Utah, Salt Lake City, UT 84112, USA
⁴ Department of Biomedical Engineering, University of Utah, Salt Lake City, Utah 84112, USA
* Correspondence: jindrich.kopecek@utah.edu; jiyuan.yang@utah.edu

Table of Contents

Figure S1. Fab'-MORF1 size exclusion chromatograms.

Figure S2. UV-Vis spectroscopy hybridization of nanoconjugates.

Figure S3. Size exclusion chromatograms of hybridized nanoconjugates.

Figure S4. CD20 and CD38 expression on Raji cells.

Figure S5. Single-target DFMT median effect plots.

Figure S6. Fab'_{DARA} + Fab'_{RTX} DFMT combination index experimental data.

Figure S7. Fab'_{DARA} + Fab'_{OBN} DFMT combination index experimental data.

Figure S8. Fab'_{ISA} + Fab'_{RTX} DFMT combination index experimental data.

Figure S9. Fab'_{ISA} + Fab'_{OBN} DFMT combination index experimental data.

Figure S10. Dual-target DFMT caspase 3 activation flow cytometry fluorescence histograms.

Figure S11. Dual-target DFMT Bax/Bcl-2 protein expression ratio.

Figure S12. Dual-target DFMT lysosomal enlargement inhibition using cathepsin B inhibitor.

Figure S13. Saline-treated mice weights and bone marrow immunostains.

Figure S14. Fab'_{RTX} DFMT single dose mice weights and bone marrow immunostains.

Figure S15. Fab'_{RTX} DFMT triple dose mice weights and bone marrow immunostains.

Figure S16. Fab'_{DARA} DFMT single dose mice weights and bone marrow immunostains.

Figure S17. Fab'_{RTX} DFMT triple dose mice weights and bone marrow immunostains.

Figure S18. Dual-target DFMT single dose mice weights and bone marrow immunostains.

Figure S19. Dual-target DFMT single dose mice weights and bone marrow immunostains.



Figure S1. Fab'-MORF1 size exclusion chromatograms of intermediates and final products.



Figure S2. UV-Vis spectrophotometry observations of morpholino hybridization between Fab'-MORF1 nanoconjugates and HSA-(MORF2)₁₀. Absorbance at λ = 260 nm was monitored for base pair complementation with varying molar equivalences of MORF1:MORF2 in a PBS pH 7.4 solution ε_{MORF1} = 278,000 M⁻¹cm⁻¹; ε_{MORF2} = 252,120 M⁻¹cm⁻¹. Hybridization is indicated by a decrease in absorbance at this wavelength.



Figure S3. Fab'-MORF1 and HSA-(MORF2)₁₀ hybridization determined by SEC with a Superdex 200 10/300 GL column, PBS (pH 7.4) as eluant at 0.4 mL/min flow rate. A 1:1 MORF1:MORF2 molar equivalent solution of Fab'-MORF1 and HSA-(MORF2)₁₀ was premixed in PBS and allowed to hybridize for 10 min. Hybridized nanoconjugate (solid) was compared to Fab'-MORF1 (dashed) and HSA-(MORF2)₁₀ (dotted).



Figure S4. Fluorescence quantification of Rituximab mAb to Daratumumab mAb binding on Raji cells indicating about 2-fold higher CD20 expression than CD38 expression. Binding was measured by treating cells with mAb for 1 h at 4 °C followed by PBS wash followed by 1 h exposure to Fluor488 goat anti-human secondary antibody. Fluorescence of secondary antibody binding was quantified using flow cytometry as a mean fluorescent intensity and normalized to unstained cells. Higher CD20 expression would suggest better response to anti-CD20 DFMT systems on this cell type.



Figure S5. Individual Fab' DFMT Median-Effect Plots, correlation data, slope and EC_{50} values reported as D_m , or x-intercept. Two replicates per Fab' DFMT system were performed.



Figure S6. Fab'_{DARA} + Fab'_{RTX} DFMT combination index experimental data.



Figure S7. Fab'_{DARA} + Fab'_{OBN} DFMT combination index experimental data.



Figure S8. Fab'_{ISA} + Fab'_{RTX} DFMT combination index experimental data.



Figure S9. Fab'_{ISA} + Fab'_{OBN} DFMT combination index experimental data.



Figure S10. Caspase 3 activation experiment histograms from flow cytometry. Corresponds with bar graph data presented in Figure 5C.



Figure S11. Bcl-2 and Bax protein expression presented as a ratio of Bax / Bcl-2 of Raji cells treated with various Fab' DFMT systems. Bcl-2 and Bax protein expression was quantified using immunostaining of the two proteins and fluorescence quantified using flow cytometry. Higher Bax-to-Bcl-2 ratio indicates a proapoptotic state in the treated cells. *** *p*<0.001, ** *p*<0.01, **p*<0.05, n.s. not significant by One-Way ANOVA and Tukey test.



Figure S12. Lysosomal enlargement inhibition of dual-target DFMT treated Raji cells with or without co-treatment with E-64 cysteine proteinase inhibitor. Corresponds to histograms presented in main text Figure 7D. *** p<0.001, *p<0.05 by One-Way ANOVA and Tukey test.



Figure S13. In vivo dual-target DFMT. Saline-treated mouse cohort. Body weights and bone marrow immunostaining for human α -CD10 and human α -CD19 antibodies.



Figure S14. In vivo dual-target DFMT. Fab'_{RTX} DFMT single dose mouse cohort. Body weights and bone marrow immunostaining with human α -CD10 and human α -CD19 antibodies. Long-term surviving mice indicated with green box.



Figure S15. In vivo dual-target DFMT. Fab'_{RTX} DFMT triple dose mouse cohort. Body weights and bone marrow immunostaining for human α -CD10 and human α -CD19 antibodies. Long-term surviving mice indicated with green box.



Figure S16. In vivo dual-target DFMT. Fab'_{DARA} DFMT single dose mouse cohort. Body weights and bone marrow immunostaining for human α -CD10 and human α -CD19 antibodies.



Figure S17. In vivo dual-target DFMT. Fab'_{DARA} DFMT triple dose mouse cohort. Body weights and bone marrow immunostaining for human α-CD10 and human α-CD19 antibodies. Long-term surviving mice indicated with green boxes.



Figure S18. In vivo dual-target DFMT. Dual-target DFMT single dose mouse cohort. Body weights and bone marrow immunostaining for human α -CD10 and human α -CD19 antibodies. Long-term surviving mice indicated with green box.



Figure S19. In vivo dual-target DFMT. Dual-target DFMT triple dose mouse cohort. Body weights and bone marrow immunostaining for human α -CD10 and human α -CD19 antibodies. Long-term surviving mice indicated with green box.